New investment in Oxcan Cancer Analytics
We are delighted to welcome Oxford Cancer Analytics (OXcan) to the We Venture Capital portfolio.
At We VC, we are committed to backing exceptional founders developing cutting-edge diagnostics for patients with critical medical need, and there’s no greater urgency than in the early detection of cancer. That’s why we´re thrilled to have co-led a $11m Series A into OXcan alongside Cross Border Impact Ventures, Eka Ventures, DigitalDx Ventures, Macmillan Cancer Support, Aurelium Ventures and OKG Capital.
OXcan is on a mission to drastically transform cancer early detection using frontier proteomics and ML approaches that can detect the deadliest cancers early, when they can still be cured. This blood test can be conducted in an affordable, minimally invasive, and routine manner with superior accuracy and localization capacity in large populations. OXcan has applied their biomarker discovery and validation platform starting from lung cancer, the leading cause of cancer mortality worldwide.
The power of the OXcan proteomics biomarker discovery platform and the data generated by Oxcan stand out against the backdrop of other liquid biopsy companies, indicating a truly superior performance in the identification of early stage lung cancer. We have been very impressed by the team to date and look forward to supporting the company in the next phase of its growth to offer its first product to patients.
Louise Warme, Head of We Venture Capital
Oxcan is headquartered in Oxford, UK.
OXcan is working with leading lung cancer screening programs worldwide to develop products
Daniel Szulc, Chief Product Officer at Oxcan
that will be fully integrated with existing clinical pathways to enhance lung cancer screening,
accelerate adoption, improve patient outcomes, and reduce healthcare system burdens from lung
cancer.
About We Venture Capital
We Venture Capital is a specialized fund investing in diagnostics, as well as tools and digital solutions in the diagnostics area. Being the corporate investment arm of Werfen, a worldwide leader in specialized diagnostics, We Venture Capital is an active investor, leveraging the network and knowledge from Werfen to the benefit of our investments.
We invest in and partner with early-stage startups close to market entry or early scale-ups, working close with our portfolio to support their growth over time. We are firm believers of technical advancement as a means to improve patient outcomes and revolutionize healthcare.
About Oxcan Cancer Analytics
Oxford Cancer Analytics (OXcan) is on a mission to drastically transform cancer early detection
and management to impact millions of lives worldwide. OXcan’s multidisciplinary team is
developing a new generation of liquid biopsy blood tests using cutting-edge proteomics and
explainable machine learning approaches that can detect the deadliest cancers early, when they
can still be cured. This blood test can be conducted in an affordable, minimally invasive, and
routine manner with superior accuracy and localization capacity in large populations. OXcan has
applied their biomarker discovery and validation platform starting from lung cancer, the leading
cause of cancer mortality worldwide, and achieved ISO13485 certification status
For more information, please visit: